Shop by goal
Popular compounds
Research resources
Recently viewed
Eloralintide
Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology.
This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.
From our community
What people say on Facebook
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io
Eloralintide
Compare pack sizes
Tap a pack to select it in the purchase panel above
Buy the 10-pack - save 51%/mg
Buy the 10-pack - save 55%/mg
Single vials ship as an add-on to a 10-vial pack - browse 10-vial packs
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, eloralintide is an appetite-focused compound that works through the amylin hunger pathway rather than the GLP-1 pathway, and is designed to be selective for the amylin receptor. It is still investigational. Here is what that looks like across the research.
Appetite & fullness
In clinical research, studied for reducing food intake through the amylin pathway - a satiety signal separate from the GLP-1 compounds.
Weight research
Human proof-of-concept and Phase 2 studies investigate meaningful body-weight reduction with once-weekly dosing.
Receptor selectivity
Research explores its preference for the amylin AMY1R receptor over the calcitonin receptor, distinguishing it from non-selective amylin analogues.
Pairing with GLP-1
Studied as a complement to incretin (GLP-1) therapy, where amylin and GLP-1 satiety pathways may add together.
Once-a-week convenience
Engineered with an albumin-binding lipid tail so research uses a single weekly subcutaneous injection.
Overview
In short: Eloralintide (LY3841136) is a selective, long-acting amylin receptor agonist engineered for once-weekly dosing, with an amylin-pathway appetite mechanism complementary to GLP-1 receptor agonists.
Key research facts
These points summarise lab themes, not human outcomes.
Eloralintide is an engineered agonist of the amylin receptor, built on the 37-amino-acid amylin scaffold. Native human amylin is unstable, forms amyloid fibrils, and has a half-life of only minutes, which made it impractical as a research tool. Eloralintide is stabilised by an intramolecular Cys2–Cys7 methylene-thioacetal bridge and protracted by acylation at Lys26 with a lipid side chain (two γ-glutamate residues plus a saturated C20 fatty diacid) that reversibly binds serum albumin for sustained circulation.
Its defining feature is receptor selectivity. Where the earlier amylin analogue cagrilintide is a non-selective agonist across the amylin receptor family and the calcitonin receptor, in-vitro characterisation reports that eloralintide preferentially activates the human AMY1R receptor over both the calcitonin receptor and the AMY3R subtype. Amylin-pathway agonism engages hindbrain and hypothalamic satiety circuits to reduce caloric intake.
Published Phase 1 proof-of-concept research reported that once-weekly eloralintide was well tolerated with minimal gastrointestinal adverse events, and a subsequently reported Phase 2 obesity programme described clinically meaningful body-weight reduction with favourable tolerability. It is being studied both as monotherapy and alongside incretin (GLP-1) therapy.
Mechanism of Action
Eloralintide is a selective amylin receptor agonist that preferentially activates AMY1R to engage satiety circuits and reduce food intake - a mechanism complementary to, but distinct from, GLP-1.
Eloralintide (LY3841136) was designed to be a selective, long-acting amylin receptor agonist. In-vitro pharmacology reports preferential activation of the human AMY1R receptor over the calcitonin receptor and the AMY3R subtype - a selectivity profile intended to isolate amylin-pathway satiety signalling. Structurally, the peptide combines a stabilising Cys2–Cys7 methylene-thioacetal bridge with a Lys26 lipid acylation (two γ-glutamate spacers and a C20 fatty diacid) that binds albumin for protraction, analogous to the acylation strategy used for other once-weekly metabolic peptides. Because the amylin pathway is mechanistically distinct from the incretin pathway, eloralintide has been investigated both as a standalone agent and in combination with GLP-1 receptor agonists.
Common Questions People Are Asking
What is eloralintide and how does it work?
Eloralintide (LY3841136) is a selective, long-acting amylin receptor agonist. It engages the amylin satiety pathway - hindbrain and hypothalamic appetite circuits - to reduce caloric intake, and in vitro it preferentially activates the human AMY1R receptor over the calcitonin receptor and AMY3R subtype. A lipid side chain at Lys26 (two γ-glutamate residues plus a C20 fatty diacid) binds serum albumin to extend its duration of action for once-weekly research dosing.
How is eloralintide different from cagrilintide?
Both are long-acting amylin analogues, but cagrilintide is a non-selective agonist across the amylin receptor family and the calcitonin receptor, whereas eloralintide is reported to be selective - preferentially activating the AMY1R amylin receptor. That selectivity is the main design difference between the two research peptides.
How is eloralintide different from a GLP-1 agonist?
GLP-1 agonists such as semaglutide activate the GLP-1 (incretin) receptor. Eloralintide activates the amylin receptor pathway. The two systems are distinct satiety circuits, which is why eloralintide has been studied both on its own and as a complement to incretin therapy.
What does the research on eloralintide actually show?
Published Phase 1 proof-of-concept research reported that once-weekly eloralintide was well tolerated with minimal gastrointestinal adverse events, and a subsequently reported Phase 2 obesity programme described clinically meaningful body-weight reduction with favourable tolerability. These are descriptive research findings for an investigational compound, not outcomes promised for any use of this research-grade material.
Is eloralintide approved or legal?
Eloralintide is an investigational compound (LY3841136) and is not an approved medicine in any jurisdiction. The material supplied here is unapproved, research-grade laboratory material sold strictly for in-vitro and preclinical research use.
How is eloralintide reconstituted and stored?
Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water by directing it down the vial wall rather than onto the powder, then swirl gently - do not shake. After reconstitution, refrigerate at 1–6 °C and protect from light. Avoid repeated freeze–thaw cycles, which can damage the fatty-acid tail.
Where can I buy Eloralintide?
Right here - Eloralintide is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.
How much does Eloralintide cost?
Eloralintide pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $350.
Is Eloralintide third-party tested?
Yes. Every Eloralintide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy Eloralintide?
Add the Eloralintide pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step. Every order ships with its batch Certificate of Analysis (COA).
What payment methods can I use to buy Eloralintide?
At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes - we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.
Research use only - all claims made on this site are for testing and research use only.
Pharmacokinetics
Research-Observed Effects
Published Research Context
In the published clinical programme, once-weekly subcutaneous eloralintide was introduced at low doses and titrated upward over several weeks. These figures describe the escalation schedules reported in published research and are recorded here as research context only.
Stacking Compatibility
Compatible compounds
Avoid combinations
Side Effects (Observed in Literature)
Common
Rare
Dose-dependent
Evidence Tier
Overall: Mixed (human + animal)
Eloralintide has human Phase 1 proof-of-concept data and a reported Phase 2 obesity programme, but it remains investigational with no approved indication in any jurisdiction. The research-grade material supplied here is unapproved laboratory material.
Tier 1 · Human clinical
Certificates, databases & peer-reviewed sources
Last reviewed: 13 July 2026 · New-U Research Compounds
Key Characteristics
Specifications
About Eloralintide (LY3841136): Selective Long-Acting Amylin Receptor Agonist Research Guide
Eloralintide (LY3841136) is a selective, long-acting amylin receptor agonist studied for obesity research. It belongs to the amylin class - a satiety pathway that is distinct from the GLP-1 (incretin) system that most metabolic research peptides target. Native human amylin forms amyloid fibrils and has a circulating half-life of minutes; eloralintide addresses this with a stabilising Cys2–Cys7 methylene-thioacetal bridge and a Lys26 lipid acylation (two γ-glutamate residues plus a C20 fatty diacid) that reversibly binds serum albumin to extend its duration of action for once-weekly research use.
The molecule's distinguishing feature is receptor selectivity. In-vitro characterisation reports that eloralintide preferentially activates the human AMY1R amylin receptor over the calcitonin receptor and the AMY3R subtype, in contrast to the non-selective amylin analogue cagrilintide. Published Phase 1 proof-of-concept research reported that once-weekly eloralintide was well tolerated with minimal gastrointestinal adverse events, and a subsequently reported Phase 2 obesity programme described clinically meaningful body-weight reduction, with the compound studied both as monotherapy and as a complement to incretin therapy.
Supplied here as a sterile lyophilised powder for in-vitro and preclinical laboratory research only. Eloralintide is an investigational compound, is not a licensed pharmaceutical product, and is not a substitute for any prescribed medication.
Customer Reviews
No customer reviews yet - be the first to share your experience.
More in Metabolic Research
Eloralintide vs related Metabolic Research compounds
Descriptive catalog comparison for research sourcing decisions - not dosing guidance.